Immunic Therapeutics Chief Scientific Officer Hella Kohlhof shares the recently released mode of action, molecular target, preclinical data for its IMU-856 asset that targets restoration of intestinal barrier function and bowel wall architecture.
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis, has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis.
IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial.
https://finance.yahoo.com/news/immunic-therapeutics-shares-imu-856-194404707.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.